

Betafuse 1 mg/g + 5 mg/g gel for dogs

Authorised

- Betamethasone valerate
- Fusidic acid hemihydrate

Product identification

Medicine name:

Betafuse 1 mg/g + 5 mg/g gel for dogs

Active substance:

Betamethasone valerate
Fusidic acid hemihydrate

Target species:

Dog

Route of administration:

Cutaneous use

Product details

Active substance and strength:

Betamethasone valerate
1.21 milligram(s) / 1.00 gram(s)
Fusidic acid hemihydrate

10.17 milligram(s) / 1.00 gram(s)

Pharmaceutical form:

Gel

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QD07CC01

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Italy

Available in:

Italy

Package description:

White polyethylene coated aluminium tubes of 30 g closed with a polypropylene cap.
White polyethylene coated aluminium tubes of 15 g closed with a polypropylene cap.

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Hybrid application (Article 13(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Norbrook Laboratories (Ireland) Limited

Marketing authorisation date:

3/02/2017

Manufacturing sites for batch release:

Norbrook Laboratories Limited

Norbrook Manufacturing Limited

Responsible authority:

Ministry Of Health

Authorisation number:

104942

Date of authorisation status change:

29/06/2021

Reference member state:

Ireland

Procedure number:

IE/V/0558/001

Concerned member states:

Austria Belgium Denmark Estonia Finland Germany Greece Italy Latvia
Lithuania Netherlands Portugal Spain Sweden

United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)

Published on: 26/01/2025

[Download](#)

Summary of Product Characteristics